

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	08/07/22

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Ippolito is a trustee of the Ippolito Trust
Date of change	12/12/2022
No. of securities held prior to change	
Vincent Peter Ippolito	5,286,493 Ordinary Shares
Vincent Peter Ippolito	12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023
Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Class	Ordinary Shares
Number acquired	1,515,151
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.066 per Ordinary Share

No. of securities held after the change	
Vincent Peter Ippolito	6,801,644 Ordinary Shares
Vincent Peter Ippolito	12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023
Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement following shareholder approval

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Matthew Callahan
Date of last notice	11/02/2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Shenasaby Pty Ltd < Shenasaby Trust> (Mr Callahan is a beneficiary of this trust)
Date of change	12/12/2022
No. of securities held prior to change	Shenasaby Pty Ltd < Shenasaby Trust> 70,738,307 Ordinary Shares
Class	Ordinary Shares
Number acquired	1,515,151
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.066 per Ordinary Share
No. of securities held after change	Shenasaby Pty Ltd < Shenasaby Trust> 72,253,458 Ordinary Shares

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement following shareholder approval
---	---

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	08/07/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	12/12/2022
No. of securities held prior to change	16,321,551 Ordinary Shares
Class	Ordinary Shares
Number acquired	Ordinary Shares
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.066 per Ordinary Share
No. of securities held after change	17,836,702 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement following shareholder approval

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	08/07/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (Including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust (Dr Washer is a trustee and beneficiary of the trust) Mal Washer Nominees Pty Ltd (Dr Washer is a director of the company)

Date of change	12/12/2022
No. of securities held prior to change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust	321,551 Ordinary Shares
Class	Ordinary Shares Unlisted Options
Number acquired	1,515,151 Ordinary Shares 5,000,000 Unlisted Options
Number disposed	-

+ See chapter 19 for defined terms.

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.066 per Ordinary Share Nil per Unlisted Option
No. of securities held after change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust Mal Washer Nominees Pty Ltd	321,551 Ordinary Shares 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 1,515,151 Ordinary Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in placement following shareholder approval Issue of Unlisted Options following shareholder approval

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Daniel Sharp
Date of last notice	22/03/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	DJMB Corporate Pty Ltd (Mr Sharp is a director of DJMB Corporate Pty Ltd)
Date of change	12/12/2022
No. of securities held prior to change DJMB Corporate Pty Ltd	1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years.
Class	Ordinary Shares
Number acquired	1,515,151
Number disposed	-

+ See chapter 19 for defined terms.

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.066 per Ordinary Share
No. of securities held after change DJMB Corporate Pty Ltd	1,515,151 Ordinary Shares 1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in placement following shareholder approval

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
---	----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.